Impact of POR*28 on the pharmacokinetics of tacrolimus and cyclosporine A in renal transplant patients

Therapeutic Drug Monitoring

Volumn 36, Issue 1, 2014, Pages 71-79

  Elens, Laure ^a,b   Hesselink, Dennis A ^c   Bouamar, Rachida ^a   Budde, Klemens ^d   De Fijter, Johannes W ^e   De Meyer, Martine ^f   Mourad, Michel ^f   Kuypers, Dirk R J ^g   Haufroid, Vincent ^b   Van Gelder, Teun ^a,c   Van Schaik, Ron H N ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c Department of Internal Medicine ^*  (Belgium)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^g UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

cyclosporin; kidney transplantation; pharmacogenetics; POR 28; tacrolimus

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 REDUCTASE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS; CYCLOSPORIN; CYP3A4 PROTEIN, HUMAN; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A; IMMUNOSUPPRESSIVE AGENT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE;

ACUTE GRAFT REJECTION; ALLELE; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DELAYED GRAFT FUNCTION; DRUG BLOOD LEVEL; DRUG EFFECT; ENZYME ACTIVITY; GENE; GENE FREQUENCY; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; KIDNEY TRANSPLANTATION; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); PHASE 4 CLINICAL TRIAL; POR 28 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; TANDEM MASS SPECTROMETRY; TIME TO TREATMENT; TREATMENT DURATION; TREATMENT OUTCOME; ADULT; CLINICAL TRIAL; DOSE RESPONSE; FOLLOW UP; GENETICS; GENOTYPE; MULTICENTER STUDY; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ALLELES; CYCLOSPORINE; CYTOCHROME P-450 CYP3A; DELAYED GRAFT FUNCTION; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLOW-UP STUDIES; GENOTYPE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; NADPH-FERRIHEMOPROTEIN REDUCTASE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; TACROLIMUS;

EID: 84892934437     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31829da6dd     Document Type: Article

References (36)

1. Venkataramanan R, Swaminathan A, Prasad T, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet. 1995;29:404-430.
2. Dai Y, Hebert MF, Isoherranen N, et al. Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab Dispos. 2006;34:836-847.
3. Dai Y, Iwanaga K, Lin YS, et al. In vitro metabolism of cyclosporine A by human kidney CYP3A5. Biochem Pharmacol. 2004;68:1889-1902.
4. Kamdem LK, Streit F, Zanger UM, et al. Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin Chem. 2005;51:1374-1381.
5. Lamba JK, Lin YS, Schuetz EG, et al. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev. 2002;54: 1271-1294.
6. Ozdemir V, Kalow W, Tang BK, et al. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics. 2000;10:373-388.
7. Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II. Clin Pharmacokinet. 2010;49: 207-221.
8. Elens L, Bouamar R, Hesselink DA, et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin Chem. 2011;57:1574-1583.
9. Elens L, van Schaik RH, Panin N, et al. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenomics. 2011;12:1383-1396.
10. Agrawal V, Choi JH, Giacomini KM, et al. Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase. Pharmacogenet Genomics. 2010;20:611-618.
11. Agrawal V, Huang N, Miller WL. Pharmacogenetics of P450 oxidoreductase: effect of sequence variants on activities of CYP1A2 and CYP2C19. Pharmacogenet Genomics. 2008;18:569-576.
12. Elens L, Nieuweboer AJ, Clarke SJ, et al. Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycin. Pharmacogenet Genomics. 2013;23:148-155.
13. Huang N, Agrawal V, Giacomini KM, et al. Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations. Proc Natl Acad Sci USA. 2008; 105:1733-1738.
14. Hubbard PA, Shen AL, Paschke R, et al. NADPH-cytochrome P450 oxidoreductase. Structural basis for hydride and electron transfer. J Biol Chem. 2001;276:29163-29170.
15. Masters BS. The journey from NADPH-cytochrome P450 oxidoreductase to nitric oxide synthases. Biochem Biophys Res Commun. 2005;338: 507-519.
16. Wang M, Roberts DL, Paschke R, et al. Three-dimensional structure of NADPH-cytochrome P450 reductase: prototype for FMN-and FADcontaining enzymes. Proc Natl Acad Sci USA. 1997;94:8411-8416.
17. Yamano S, Aoyama T, McBride OW, et al. Human NADPH-P450 oxidoreductase: complementary DNA cloning, sequence and vaccinia virus-mediated expression and localization of the CYPOR gene to chromosome 7. Mol Pharmacol. 1989;36:83-88.
18. Gomes AM, Winter S, Klein K, et al. Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation. Pharmacogenomics. 2009;10:579-599.
19. Gomes LG, Huang N, Agrawal V, et al. The common P450 oxidoreductase variant A503V is not a modifier gene for 21-hydroxylase deficiency. J Clin Endocrinol Metab. 2008;93:2913-2916.
20. Oneda B, Crettol S, Jaquenoud Sirot E, et al. The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test. Pharmacogenet Genomics. 2009;19: 877-883.
21. Sandee D, Morrissey K, Agrawal V, et al. Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro. Pharmacogenet Genomics. 2010;20:677-686.
22. de Jonge H, Metalidis C, Naesens M, et al. The P450 oxidoreductase *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients. Pharmacogenomics. 2011;12:1281-1291.
23. Zhang JJ, Zhang H, Ding XL, et al. Effect of the P450 oxidoreductase *28 polymorphism on the pharmacokinetics of tacrolimus in Chinese healthy male volunteers. Eur J Clin Pharmacol. 2012;69:807-812.
24. Kronbach T, Fischer V, Meyer UA. Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther. 1988;43:630-635.
25. van Gelder T, Silva HT, de Fijter JW, et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation. 2008;86: 1043-1051.
26. van Schaik RH, van Agteren M, de Fijter JW, et al. UGT1A9-275T.A/-2152C.T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients. Clin Pharmacol Ther. 2009;86:319-327.
27. van Agteren M, Armstrong VW, van Schaik RH, et al. AcylMPAG plasma concentrations and mycophenolic acid-related side effects in patients undergoing renal transplantation are not related to the UGT2B7-840G.A gene polymorphism. Ther Drug Monit. 2008;30:439-444.
28. Bouamar R, Hesselink DA, van Schaik RH, et al. Polymorphisms in CYP3A5, CYP3A4, and ABCB1 are not associated with cyclosporine pharmacokinetics nor with cyclosporine clinical End points after renal transplantation. Ther Drug Monit. 2011;33:178-184.
29. Elens L, Bouamar R, Hesselink DA, et al. The new CYP3A4 intron 6 C.T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients. Pharmacogenet Genomics. 2012;22:373-380.
30. Hesselink DA, van Schaik RH, van Agteren M, et al. CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients. Pharmacogenet Genomics. 2008;18:339-348.
31. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
32. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int. 1999;55:713-723.
33. Haufroid V, Mourad M, Van Kerckhove V, et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics. 2004;14:147-154.
34. Hart SN, Wang S, Nakamoto K, et al. Genetic polymorphisms in cytochrome P450 oxidoreductase influence microsomal P450-catalyzed drug metabolism. Pharmacogenet Genomics. 2008;18:11-24.
35. Ingelman-Sundberg M, Sim SC, Gomez A, et al. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther. 2007;116:496-526.
36. Ioannidis JP. Why most published research findings are false. PLoS Med. 2005;2:e124.